SAN DIEGO, CA and PORTLAND, OR, Mar 05, 2012 (MARKETWIRE via COMTEX) -- Medistem Inc. (pinksheets:MEDS), in partnership with its Russian licensee, ERCell, announced the signing of a letter of intent* to begin clinical trials using Medistem's Endometrial Regenerative Cells (ERC) stem cells for renal, lung and peripheral artery disease. Trials will be conducted in [...]
Medistem Inc announced today treatment of 3 heart failure patients in the Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC) trial. The trial is aimed at assessing safety and efficacy of the company's Endometrial Regenerative Cell (ERC) stem cell product in 60 heart failure patients who have no available [...]
The clinical trial, Non-Revascularizable IschEmic Cardiomyopathy treated with Retrograde COronary Sinus Venous DElivery of Cell TheRapy (RECOVER-ERC), is being led by Principle Investigator Dr. Leo Bockeria, Chairman of the Backulev Center http://www.bakulev.ru/en/about/director/. The Backulev Center is Russia's premier institute for cardiovascular surgery and cardiology. Every year the Backulev Center performs approximately 30,000 diagnostic and treatment [...]
Zhang et al. Journal of Translational Medicine Diabetes is associated with numerous “secondary complications” including premature heart disease, renal failure, critical limb ischemia (an advanced form of peripheral artery disease) and diabetic retinopathy. One of the common features of these secondary complications is that they are all associated with low levels of circulating endothelial progenitor [...]
New Approach Opens Door to Expanded Uses of Cord Blood Stem Cells Beike Biotechnology Press Release Beiki Biotechnology and Medistem Inc (MEDS.PK) report positive safety data in 114 patients with neurological conditions treated using Beiki’s proprietary cord blood stem cell transplantation protocol. In the peer-reviewed paper “Safety evaluation of allogeneic umbilical cord blood mononuclear cell [...]
Medistem Inc. (PINKSHEETS: MEDS) announced today publication of a peer reviewed paper identifying a molecule found on the company’s lead product, the universal donor Endometrial Regenerative Cell (ERC), as a key component of cellular escape from immune attack. The study, entitled “Resistance of neonatal porcine Sertoli cells to human xenoantibody and complement-mediated lysis is associated [...]
SAN DIEGO, CA – (Marketwire - June 21, 2010) - Medistem Inc. Medistem Inc. together with the Stem Cell Institute reported today publication in the peer reviewed journal Cellular Immunology its paper titled "Autologous stromal vascular fraction cells: A tool for facilitating tolerance in rheumatic disease," which describes the first use of a patient's own [...]